Research
Hormonal
Once-weekly subcutaneous semaglutide at 1.0mg significantly lowers HbA1c and promotes weight loss in patients with Type 2 Diabetes compared to other glucose-lowering therapies.
For patients with Type 2 Diabetes, once-weekly subcutaneous semaglutide at 1.0mg is a highly effective treatment for lowering HbA1c (reducing it by 1.6-1.9%) and promoting weight loss. It is superior to other common glucose-lowering medications and even other GLP-1 RAs like dulaglutide in head-to-head comparisons.
StrongSupportsVERY_HIGH confidence
The fall in HbA1c was significantly greater for both doses of semaglutide versus comparator and ranged from 13.2-16.0 mmol/mol (1.2-1.5%) for 0.5mg QW and 16.8-20.2mmol/mol (1.6-1.9%) for semaglutide 1.0mg QW.
Why this rating
Based on Phase 3 RCTs (SUSTAIN 1-5) with 8,416 participants.
Source
Recent developments in <scp>GLP‐1RA</scp> therapy: A review of the latest evidence of efficacy and safety and differences within the class
Evie Bain et al. · Diabetes Obesity and Metabolism · 2021
narrative_reviewCited 18×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →